QuantuMDx has confirmed its rapid PCR device, SARS-CoV-2 assays for open PCR platforms and its future respiratory panel (SARS-CoV-2, Flu A, Flu B and RSV A/B), will continue to detect all virus strains, including the Omicron variant.
The alterations in the variant's genome sequences publicly available in GISAID (the online SARS-CoV-2 genome sequence database) did not affect the primer or probe locations, according to in silico research. This is a testament to QuantuMDx's superior assay design, and it further emphasises the company's product quality.
“QuantuMDx's tests will continue to detect all virus strains.“
QuantuMDx's Chief Executive, Jonathan O'Halloran, stated: "Following the detection of this new variant, we have performed a detailed analysis of the mutations to fully assess the reliability of our existing tests and Q-POC. Our assay design strategy, to include three targets, where most only target one or two regions of the SARS-CoV-2 genome, is being proven to be a robust one and with all the new variants continually emerging, we are confident that our tests and device remain able to detect all known variants."